Treatment of carcinoma of the lung with 1-acetyl-2-picolinoylhydrazine (NSC-68626).
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced; D010847:Picolines / Q000009:adverse effects / Q000627:therapeutic use*; D012893:Sleep Wake Disorders / Q000139:chemically induced; D014717:Vertigo / Q000139:chemically induced
D000970:Antineoplastic Agents; D006834:Hydrazines; D010847:Picolines